Zhiyu Peng

Dr. Zhiyu Peng

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2020 in Materials
Verified
Journal Article
Open access
PDF file
WPWei Peng
Wei Peng
ZPZhiyu Peng
Zhiyu Peng
PTPei Tang
Pei Tang
HSHuan Sun
Huan Sun
HLHaoyuan Lei
Haoyuan Lei
YWYongwei Wang
Yongwei Wang
Plastic surgery is a broad field, including maxillofacial surgery, skin flaps and grafts, liposuction and body contouring, breast surgery, and facial cosmetic procedures. Due to the requirements of plastic surgery for the biological safety of materials, biomaterials are widely used because of its superior biocompatibility and biodegradability. Currently, there are many kinds of biomaterials clinically used in plastic surgery and their applications are diverse. Moreover, with the rise of three-dimensional printing technology in recent years, the macroscopically more precise and personalized bio-scaffolding materials with microporous structure have made good progress, which is thought to bring new development to biomaterials. Therefore, in this paper, we reviewed the plastic surgery biomaterials and current progress in their 3D manufacturing technology.

1 January 2020 in Nanotechnology Reviews
Verified
Journal Article
Open access
PDF file
ZPZhiyu Peng
Zhiyu Peng
PTPei Tang
Pei Tang
LZLi Zhao
Li Zhao
LWLina Wu
Lina Wu
XXXiujuan Xu
Xiujuan Xu
ZLZhengyong Li
Zhengyong Li
Adipose tissue reconstruction is an important technique for soft tissue defects caused by facial plastic surgery and trauma. Adipose tissue reconstruction can be repaired by fat transplantation and biomaterial filling, but there are some problems in fat transplantation, such as second operation and limited resources. The application of advanced artificial biomaterials is a promising strategy. In this paper, injectable biomaterials and three-dimensional (3D) tissue-engineered scaffold materials for adipose tissue reconstruction in plastic surgery are reviewed. Injectable biomaterials include natural biomaterials and artificial biomaterials, which generally have problems such as high absorptivity of fillers, repeated injection, and rejection. In recent years, the technology of new 3D tissue-engineering scaffold materials with adipose-derived stem cells (ADSCs) and porous scaffold as the core has made good progress in fat reconstruction, which is expected to solve the current problem of clinical adipose tissue reconstruction, and various biomaterials preparation technology and transformation research also provide the basis for clinical transformation of fat tissue reconstruction.

26 November 2019 in International Orthopaedics
Verified
Journal Article
Closed access
PDF file
JYJin Yang
Jin Yang
CGChuan Guo
Chuan Guo
QKQingquan Kong
Qingquan Kong
BZBin Zhang
Bin Zhang
YWYu Wang
Yu Wang
DZDongfeng Zhang
Dongfeng Zhang

8 August 2025 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Open access
JCJing Chen
Jing Chen
YMYuanzheng Mao
Yuanzheng Mao
ZPZhiyu Peng
Zhiyu Peng
Venous thromboembolism (VTE) remains a major contributor to postoperative morbidity and mortality in patients undergoing lung cancer surgery. This study aims to identify perioperative risk factors associated with VTE development following such procedures. We performed an exhaustive search of PUBMED and EMBASE from inception to November 1, 2023, using terms related to VTE following lung cancer surgery. A random-effects meta-analysis was performed to calculate the pooled incidence and odds ratios (ORs) for risk factors. Of 3,576 screened studies, 13 met eligibility criteria for qualitative synthesis, and 11 studies (53,382 patients) were included in the meta-analysis. The pooled incidence of postoperative VTE was 1.82% (971 cases). Significant risk factors included advanced age (standardized mean difference [SMD] 0.43, 95% CI 0.22-0.63; I2 = 59.9%), prolonged surgical duration (SMD 0.58, 95% CI 0.24-0.92; I2 = 81.2%), open thoracotomy (OR 1.77, 95% CI 1.50-2.09; I2 = 19.9%), TNM stage > 1 (OR = 1.81, 95% CI 1.53-2.13; I2 = 39.8%), adenocarcinoma histology (OR = 1.29, 95% CI 1.08-1.53; I2 = 1.2%), and major lung resection (OR = 1.51, 95% CI 1.24-1.83; I2 = 0.0%). This study highlights key modifiable and non-modifiable risk factors for postoperative VTE in lung cancer surgery patients. These findings support individualized risk stratification and targeted thromboprophylaxis strategies to improve clinical outcomes.

4 March 2024 in International Journal of Surgery
Verified
Journal Article
Open access
LLLinchuan Liang
Linchuan Liang
ZPZhiyu Peng
Zhiyu Peng
JMJian-Dong Mei
Jian-Dong Mei
An abstract is unavailable. This article is available as a PDF only.

18 April 2021
Verified
Report
Closed access
ZPZhiyu Peng
Zhiyu Peng
HLHuahang Lin
Huahang Lin
KZKe Zhou
Ke Zhou
SDSenyi Deng
Senyi Deng
JMJiandong Mei
Jiandong Mei